Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$6.53 USD
+0.49 (8.11%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.52 -0.01 (-0.15%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/05/2025
Time: BMO |
6/2025 | $-0.35 | 0.00% |
Earnings Summary
For their last quarter, Tango Therapeutics (TNGX) reported earnings of -$0.36 per share, missing the Zacks Consensus Estimate of -$0.34 per share. This reflects a negative earnings surprise of 5.88%. Look out for TNGX's next earnings release on August 05, 2025. For the next earning release, we expect the company to report earnings of -$0.35 per share, reflecting a year-over-year decrease of 45.83%.
Earnings History
Price & Consensus
Zacks News for TNGX
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
TNGX FAQs
Tango Therapeutics, Inc. (TNGX) has announced they will report their next quarter earnings on August 05, 2025. For the next earning release, we expect the company to report earnings of $-0.35 per share, reflecting a year-over-year decrease of -45.83%.
Tango Therapeutics, Inc. has announced they will report their previous quarter earnings after the close of the market on August 05, 2025.
The Zacks Consensus Estimate for Tango Therapeutics, Inc. (TNGX) for the quarter ending June 2025 is $-0.35 a share. We expect Tango Therapeutics, Inc. (TNGX) to report earnings in line with the consensus estimate of $-0.35 per share
In the earnings report for the quarter ending in June 2024, Tango Therapeutics, Inc. (TNGX) announced earnings of $-0.24 per share versus the Zacks Consensus Estimate of $-0.34 per share, representing a surprise of -29.41%.